Panobinostat submitted to the FDA for approval as a new treatment for myeloma

Novartis, the Swiss pharmaceutical company, has announced that the US Food and Drug Administration (FDA) has granted priority review for its licensing application of panobinostat, a histone deacetylase inhibitor, as a new treatment for myeloma. The submission is based on the results of the PANORAMA-1 trial involving panobinostat in combination with VelcadeĀ® and dexamethasone in…

Details